How Liquid Biopsies Detect Cancer From a Blood Test

A Blood Draw Instead of Surgery

Traditional cancer diagnosis has long relied on the tissue biopsy — a surgeon cuts into the body to extract a sample of a suspected tumor for laboratory analysis. It works, but it is invasive, painful, sometimes impossible if a tumor is lodged in an unreachable location, and provides only a snapshot of a single site. Liquid biopsies are rewriting that equation. With nothing more than a routine blood draw, clinicians can now hunt for molecular traces of cancer circulating silently in a patient's bloodstream.

What Is a Liquid Biopsy?

A liquid biopsy is a laboratory test that analyzes blood — or occasionally other body fluids like urine or cerebrospinal fluid — for biological material shed by tumors. The most important target is circulating tumor DNA (ctDNA): tiny fragments of genetic material released into the bloodstream when cancer cells die, either through programmed cell death (apoptosis) or through the spillage that accompanies rapid tumor growth.

As tumors grow, they constantly shed these DNA fragments. Because blood circulates through virtually every tissue in the body, a single blood draw can, in principle, carry signals from tumors anywhere — including sites too small or too inaccessible for conventional biopsy, according to the National Cancer Institute.

How It Works: The Science of ctDNA

The blood of a healthy person contains small amounts of cell-free DNA (cfDNA) — genetic fragments from normal cell turnover. In cancer patients, a fraction of this cfDNA comes from tumor cells, and this is the ctDNA that liquid biopsy tests are designed to find and characterize.

The challenge is that ctDNA can make up a vanishingly small proportion of all cfDNA in the blood — sometimes less than 0.1% — particularly in early-stage cancers. Detecting it therefore requires extremely sensitive molecular techniques, chief among them:

• Next-generation sequencing (NGS): Reads millions of DNA fragments simultaneously, identifying cancer-specific mutations with high accuracy.
• Digital PCR (dPCR): Partitions a sample into thousands of tiny reactions to count individual mutant DNA molecules with precision.
• Methylation profiling: Detects abnormal chemical tags on DNA that are characteristic of tumor cells, and can even suggest which organ the cancer originated from.

Machine learning algorithms are increasingly applied on top of these techniques to distinguish true cancer signals from background noise, boosting both sensitivity and specificity, as described in a 2024 review published in Signal Transduction and Targeted Therapy.

What Liquid Biopsies Are Used For

Treatment Guidance in Advanced Cancer

The most established clinical use is identifying the specific genetic mutations driving a patient's cancer so doctors can select the right targeted therapy. The FDA has approved several liquid biopsy companion diagnostic tests for this purpose — for example, detecting EGFR or KRAS mutations in lung and colorectal cancers when tissue sampling is not feasible, according to MD Anderson Cancer Center.

Monitoring Treatment Response

Because ctDNA levels in the blood rise and fall in response to how well a treatment is working, serial liquid biopsies can serve as a real-time dashboard of therapy effectiveness — often weeks before changes appear on imaging scans.

Detecting Minimal Residual Disease

After a patient finishes curative treatment, persistent ctDNA in the blood can signal that microscopic cancer cells remain — allowing doctors to intervene before a full relapse becomes visible, according to Memorial Sloan Kettering Cancer Center.

Early Detection Screening

The most ambitious frontier is using liquid biopsies to screen for cancer in healthy or high-risk populations before symptoms appear. Multi-cancer early detection (MCED) tests — such as those being trialed in large NHS and US studies — aim to detect dozens of cancer types from a single blood draw. Early results are promising but sensitivity for stage I cancers remains a significant hurdle.

Limitations and Challenges

Despite the excitement, liquid biopsies are not yet a routine screening tool for the general population. Key limitations include:

• Low sensitivity in early disease: When tumors are small, they shed very little DNA, making detection unreliable.
• False positives: Mutations from aging blood cells (clonal hematopoiesis) can mimic cancer signals.
• No tissue architecture: Unlike a tissue biopsy, a liquid biopsy cannot reveal how a tumor looks under a microscope or how it has invaded surrounding structures.
• Regulatory and insurance barriers: Many tests remain investigational, and coverage is inconsistent.

The Road Ahead

Researchers are working to increase the volume of blood analyzed, refine machine learning models, and combine ctDNA with other blood-based markers — such as proteins and exosomal RNA — to push sensitivity higher. A multi-analyte approach to pancreatic cancer, one of the hardest cancers to catch early, has already demonstrated over 90% accuracy in research settings, according to a review published in PubMed Central.

The vision is compelling: a routine annual blood test that screens for dozens of cancers simultaneously, catching them early enough for curative treatment. Liquid biopsies will not replace tissue biopsies entirely — pathologists still need physical samples to confirm diagnoses and study tumor microenvironments. But as a complement to traditional methods, they are rapidly moving from research laboratories into everyday oncology care.